Light-activated chimeric opsins and methods of using the same

Patent metadata

Field	Value
Publication number	US-9850290-B2
Application number	US-201615147772-A
Country	US
Kind code	B2
Filing date	May 5, 2016
Priority date	Nov 5, 2010
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

Provided herein are compositions comprising light-activated chimeric proteins expressed on plasma membranes and methods of using the same to selectively depolarize excitatory or inhibitory neurons.

First claim

What is claimed is:

1. A method for identifying a chemical compound that selectively inhibits the depolarization of excitatory or inhibitory neurons residing in the same microcircuit, the method comprising:
(a) selectively depolarizing an excitatory neuron comprising a first light-activated protein with light having a first wavelength or selectively depolarizing an inhibitory neuron comprising a second light-activated protein with light having a second wavelength; wherein the first or the second light activated protein is a chimeric protein comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1;
(b) measuring an excitatory post synaptic potential (EPSP) in response to selectively depolarizing the excitatory neuron comprising the first light-activated protein or measuring an inhibitory post synaptic current (IPSC) in response to selectively depolarizing an inhibitory neuron comprising the second light-activated protein;
(c) contacting the excitatory neuron or the inhibitory neuron with a chemical compound; and
(d) measuring the excitatory post synaptic potential (EPSP) or measuring the inhibitory post synaptic current (IPSC) to determine if contacting either the excitatory neuron or the inhibitory neuron with the chemical compound selectively inhibits the depolarization of either neuron.

2. The method of claim 1 , wherein the first light-activated protein comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 1, 3, 5, or 7.

3. The method of claim 1 , wherein the first light-activated protein is activated by green light or the second light-activated protein is activated by violet light.

4. The method of claim 1 , wherein the inhibitory or excitatory neuron is in a living non-human animal.

5. The method of claim 1 , wherein the inhibitory or excitatory neuron is in living brain slices from a non-human animal.

6. The method of claim 1 , wherein the inhibitory or excitatory neuron is from the prefrontal cortex.

7. The method of claim 1 , wherein the excitatory neuron comprises a pyramidal neuron or the inhibitory neuron comprises a parvalbumin neuron.

8. The method of claim 1 , wherein the chemical compound is a member of a combinatorial chemical library.

9. The method of claim 1 , further comprising assaying the chemical compound on cardiac tissue to determine if the compound adversely affects cardiac action potential.

10. The method of claim 1 , wherein the second light-activated protein comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:11, 12, 13, or 14.

11. A light-responsive chimeric polypeptide comprising, in order from N-terminus to C-terminus:
a) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 1-163 of the ChR1 amino acid sequence set forth in SEQ ID NO:16; and
b) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 120-300 of SEQ ID NO:17.

12. The light-responsive chimeric polypeptide of claim 11 , wherein the polypeptide is activated by light of a wavelength between about 540 nm to about 560 nm.

13. The chimeric polypeptide of claim 11 , further comprising a C-terminal trafficking signal.

14. The chimeric polypeptide of claim 13 , wherein the trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:15).

15. The chimeric polypeptide of claim 11 , wherein the light-responsive chimeric polypeptide comprises a Glu to Thr amino acid substitution at position 122 relative to the amino acid sequence set forth in SEQ ID NO:16.

16. The chimeric polypeptide of claim 11 , wherein the light-responsive chimeric polypeptide comprises a Glu to Thr amino acid substitution at position 162 relative to the amino acid sequence set forth in SEQ ID NO:16.

17. The chimeric polypeptide of claim 11 , wherein the light-responsive chimeric polypeptide comprises a Glu to Thr amino acid substitution at position 122 and a Glu to Thr amino acid substitution at position 162 relative to the amino acid sequence set forth in SEQ ID NO:16.

18. A polynucleotide comprising a nucleotide sequence encoding a light-responsive chimeric polypeptide comprising, in order from N-terminus to C-terminus:
a) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 1-163 of the ChR1 amino acid sequence set forth in SEQ ID NO: 16; and
b) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 120-300 of SEQ ID NO: 17.

19. The polynucleotide of claim 18 , wherein the polynucleotide is an expression vector.

20. The polynucleotide of claim 19 , wherein the expression vector is a viral vector.

21. The polynucleotide of claim 18 , wherein the nucleotide sequence is operably linked to a promoter.

Assignees

• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Yizhar Ofer
• Fenno Lief
• Hegemann Peter
• Prigge Matthias

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• G01N33/5058

  Neurological cells · CPC title

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title